nach oben

Current Diabetes Reports

Erschienen in:

01.03.2024 | REVIEW

Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: a Review

verfasst von: Reza Pishdad, Paul G. Auwaerter, Rita R. Kalyani

Erschienen in: Current Diabetes Reports | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The aim of this review is to focus on epidemiology, pathogenesis, risk factors, management, and complications of UTI in people with diabetes as well as reviewing the association of SGLT-2 inhibitors with genitourinary infections.

Recent Findings

Individuals diagnosed with T2DM are more prone to experiencing UTIs and recurrent UTIs compared to individuals without T2DM. T2DM is associated with an increased risk of any genitourinary infections (GUI), urinary tract infections (UTIs), and genital infections (GIs) across all age categories. SGLT2 inhibitors are a relatively new class of anti-hyperglycemic agents, and studies suggest that they are associated with an increased risk of genitourinary infections. The management of diabetes and lifestyle modifications with a patient-centric approach are the most recognized methods for preventing critical long-term complications including genitourinary manifestations of diabetes.

Summary

The available data regarding the association of SGLT-2 inhibitors with genitourinary infections is more comprehensive compared to that with UTIs. Further research is needed to better understand the mechanisms underlining the association between SGLT-2 inhibitors and genital infections and UTIs.

Casqueiro J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab. 2012;16(Suppl1):S27-36.PubMedPubMedCentral

Garg V, Bose A, Jindal J, Goyal A. Comparison of clinical presentation and risk factors in diabetic and non-diabetic females with urinary tract infection assessed as per the European Association of Urology Classification. J Clin Diagn Res. 2015;9(6):PC12-4.PubMedPubMedCentral

Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. JAMA. 2014;312(16):1677–84.PubMedCrossRef

Fu AZ, Iglay K, Qiu Y, Engel S, Shankar R, Brodovicz K. Risk characterization for urinary tract infections in subjects with newly diagnosed type 2 diabetes. J Diabetes Complicat. 2014;28(6):805–10.CrossRef

Sewify M, Nair S, Warsame S, Murad M, Alhubail A, Behbehani K, et al. Prevalence of urinary tract infection and antimicrobial susceptibility among diabetic patients with controlled and uncontrolled glycemia in Kuwait. J Diabetes Res. 2016;2016:6573215.PubMedCrossRef

Nichols GA, Brodovicz KG, Kimes TM, Déruaz-Luyet A, Bartels DB. Prevalence and incidence of urinary tract and genital infections among patients with and without type 2 diabetes. J Diabetes Complicat. 2017;31(11):1587–91.CrossRef

Wilke T, Boettger B, Berg B, Groth A, Mueller S, Botteman M, et al. Epidemiology of urinary tract infections in type 2 diabetes mellitus patients: an analysis based on a large sample of 456,586 German T2DM patients. J Diabetes Complicat. 2015;29(8):1015–23.CrossRef

Hirji I, Guo Z, Andersson SW, Hammar N, Gomez-Caminero A. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J Diabetes Complicat. 2012;26(6):513–6.CrossRef

MeC R-M, Pascual-Pérez R, Orozco-Beltrán D, Pérez-Barba C, Pedrera-Carbonell V. Risk factors for the development and persistence of asymptomatic bacteriuria in patients with type 2 diabetes. Med Clin (Barc). 2005;125(16):606–10.

10.

Janifer J, Geethalakshmi S, Satyavani K, Viswanathan V. Prevalence of lower urinary tract infection in South Indian type 2 diabetic subjects. Indian J Nephrol. 2009;19(3):107–11.PubMedPubMedCentralCrossRef

11.

Goswami R, Bal CS, Tejaswi S, Punjabi GV, Kapil A, Kochupillai N. Prevalence of urinary tract infection and renal scars in patients with diabetes mellitus. Diabetes Res Clin Pract. 2001;53(3):181–6.PubMedCrossRef

12.

Tourret J, Bagnis CI, Denamur E. Urinary tract infections in diabetic patients. Rev Prat. 2014;64(7):980–3.PubMed

13.

Hammar N, Farahmand B, Gran M, Joelson S, Andersson SW. Incidence of urinary tract infection in patients with type 2 diabetes. Experience from adverse event reporting in clinical trials. Pharmacoepidemiol Drug Saf. 2010;19(12):1287–92.PubMedCrossRef

14.

Boroumand MA, Sam L, Abbasi SH, Salarifar M, Kassaian E, Forghani S. Asymptomatic bacteriuria in type 2 Iranian diabetic women: a cross sectional study. BMC Womens Health. 2006;6:4.PubMedPubMedCentralCrossRef

15.

de Lastours V, Foxman B. Urinary tract infection in diabetes: epidemiologic considerations. Curr Infect Dis Rep. 2014;16(1):389.PubMedCrossRef

16.

Zhanel GG, Harding GK, Nicolle LE. Asymptomatic bacteriuria in patients with diabetes mellitus. Rev Infect Dis. 1991;13(1):150–4.PubMedCrossRef

17.

Harwalkar A, Gupta S, Rao A, Srinivasa H. Prevalence of virulence factors and phylogenetic characterization of uropathogenic Escherichia coli causing urinary tract infection in patients with and without diabetes mellitus. Trans R Soc Trop Med Hyg. 2015;109(12):769–74.PubMed

18.

Lye WC, Chan RK, Lee EJ, Kumarasinghe G. Urinary tract infections in patients with diabetes mellitus. J Infect. 1992;24(2):169–74.PubMedCrossRef

19.

Bonadio M, Costarelli S, Morelli G, Tartaglia T. The influence of diabetes mellitus on the spectrum of uropathogens and the antimicrobial resistance in elderly adult patients with urinary tract infection. BMC Infect Dis. 2006;6:54.PubMedPubMedCentralCrossRef

20.

Chen HS, Su LT, Lin SZ, Sung FC, Ko MC, Li CY. Increased risk of urinary tract calculi among patients with diabetes mellitus–a population-based cohort study. Urology. 2012;79(1):86–92.PubMedCrossRef

21.

James R, Hijaz A. Lower urinary tract symptoms in women with diabetes mellitus: a current review. Curr Urol Rep. 2014;15(10):440.PubMedCrossRef

22.

Geerlings SE. Urinary tract infections in patients with diabetes mellitus: epidemiology, pathogenesis and treatment. Int J Antimicrob Agents. 2008;31(Suppl 1):S54–7.PubMedCrossRef

23.

Hoepelman IM. Urinary tract infection in patients with diabetes mellitus. Int J Antimicrob Agents. 1994;4(2):113–6.PubMedCrossRef

24.

Hoepelman AI, Meiland R, Geerlings SE. Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents. 2003;22(Suppl 2):35–43.PubMedCrossRef

25.

Nitzan O, Elias M, Chazan B, Saliba W. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab Syndr Obes. 2015;8:129–36.PubMedPubMedCentral

26.

Chen SL, Jackson SL, Boyko EJ. Diabetes mellitus and urinary tract infection: epidemiology, pathogenesis and proposed studies in animal models. J Urol. 2009;182(6 Suppl):S51–6.PubMed

27.

Geerlings SE, Meiland R, Hoepelman IM. Urinary tract infections in women with diabetes mellitus. Ned Tijdschr Geneeskd. 2001;145(38):1832–6.PubMed

28.

Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet TJ, Hoepelman AI, et al. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care. 2000;23(12):1737–41.PubMedCrossRef

29.

Al-Rubeaan KA, Moharram O, Al-Naqeb D, Hassan A, Rafiullah MR. Prevalence of urinary tract infection and risk factors among Saudi patients with diabetes. World J Urol. 2013;31(3):573–8.PubMedCrossRef

30.

Sanden AK, Johansen MB, Pedersen L, Lervang HH, Schønheyder HC, Thomsen RW. Change from oral antidiabetic therapy to insulin and risk of urinary tract infections in type 2 diabetic patients: a population-based prescription study. J Diabetes Complicat. 2010;24(6):375–81.CrossRef

31.

NjomnangSoh P, Vidal F, Huyghe E, Gourdy P, Halimi JM, Bouhanick B. Urinary and genital infections in patients with diabetes: how to diagnose and how to treat. Diabetes Metab. 2016;42(1):16–24.CrossRef

32.

•• Benjamin T, Schumacher C. Characterization of risk factors for genitourinary infections with sodium-glucose cotransporter-2 inhibitors. Pharmacotherapy. 2020;40(10):1002–11.While certain factors like estimated glomerular filtration rate (eGFR) and a history of genitourinary infections increase the risk, the overall incidence of infections related to SGLT2 inhibitors might be lower than initially suggested.PubMedCrossRef

33.

•• Staplin N, Roddick AJ, Emberson J, Reith C, Riding A, Wonnacott A, et al. Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine. 2021;41:101163.The observed impacts of SGLT-2 inhibition on essential safety and effectiveness outcomes remain consistent among various patient groups studied.PubMedPubMedCentralCrossRef

34.

Schneeberger C, Kazemier BM, Geerlings SE. Asymptomatic bacteriuria and urinary tract infections in special patient groups: women with diabetes mellitus and pregnant women. Curr Opin Infect Dis. 2014;27(1):108–14.PubMedCrossRef

35.

Aggarwal A, Wadhwa R, Kapoor D, Khanna R. High prevalence of genital mycotic infections with sodium-glucose co-transporter 2 inhibitors among Indian patients with type 2 diabetes. Indian J Endocrinol Metab. 2019;23(1):9–13.PubMedPubMedCentralCrossRef

36.

Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019;171(4):248–56.PubMedPubMedCentralCrossRef

37.

Rizzi M, Trevisan R. Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors. Nutr Metab Cardiovasc Dis. 2016;26(11):963–70.PubMedCrossRef

38.

•• Wiegley N, So PN. Sodium-glucose cotransporter 2 inhibitors and urinary tract infection: is there room for real concern? Kidney360. 2022;3(11):1991–3.This study serves as a pivotal resource providing reassurance to both patients and prescribers, thereby advocating for the broader and confident utilization of SGLT-2 I in clinical practice for enhanced kidney and heart protection.

39.

Halimi S, Vergès B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 2014;40(6 Suppl 1):S28-34.PubMedCrossRef

40.

Yang H, Choi E, Park E, Na E, Chung SY, Kim B, et al. Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: a retrospective cohort study in Korea. Pharmacol Res Perspect. 2022;10(1):e00910.PubMedPubMedCentralCrossRef

41.

Liao HW, Wu YL, Sue YM, Lee M, Ovbiagele B. Sodium-glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Endocrinol Diabetes Metab. 2019;2(1):e00050.PubMedCrossRef

42.

Liu D, Chen H, Song F, Ahmed MA, Wu H. Adverse drug events observed with the novel sodium/glucose co-transporter 2 inhibitor ipragliflozin for the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized studies. Adv Ther. 2020;37(10):4356–69.PubMedCrossRef

43.

Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55(5):503–14.PubMedCrossRef

44.

Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complicat. 2013;27(5):473–8.CrossRef

45.

•• Zheng Z, He D, Chen J, Xie X, Lu Y, Wu B, et al. Risk of urinary tract infection in patients with type 2 diabetes mellitus treated with dapagliflozin: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2023;43(4):209–25.This study encompasses a comprehensive examination of 42 RCTs involving 35,938 patients, revealing that dapagliflozin administration poses a higher UTI risk compared to both placebo and other active treatments, particularly emphasizing heightened risks with higher dosages of dapagliflozin.PubMedCrossRef

46.

•• Liew A, Lydia A, Matawaran BJ, Susantitaphong P, Tran HTB, Lim LL. Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries-an expert consensus statement. Nephrology (Carlton). 2023;28(8):415–24.This study critically addresses the discrepancy between the well-documented clinical benefits of SGLT-2 inhibitors and their notably low utilization rates, notably prevalent within low-resource settings. It emphasizes the contributing factors to this pattern, such as clinician unfamiliarity with the evolving organ-protective role attributed to these agents, apprehensions concerning potential adverse effects, and uncertainties regarding the safety profiles specifically in elderly populations.PubMedCrossRef

47.

Pratley RE, Cannon CP, Cherney DZI, Cosentino F, McGuire DK, Essex MN, et al. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. Lancet Healthy Longev. 2023;4(4):e143–54.PubMedCrossRef

48.

Boyko EJ, Fihn SD, Scholes D, Chen CL, Normand EH, Yarbro P. Diabetes and the risk of acute urinary tract infection among postmenopausal women. Diabetes Care. 2002;25(10):1778–83.PubMedCrossRef

49.

Tandogdu Z, Cai T, Koves B, Wagenlehner F, Bjerklund-Johansen TE. Urinary tract infections in immunocompromised patients with diabetes, chronic kidney disease, and kidney transplant. Eur Urol Focus. 2016;2(4):394–9.PubMedCrossRef

50.

Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40(5):643–54.PubMedCrossRef

51.

Nicolle LE. Asymptomatic bacteriuria. Curr Opin Infect Dis. 2014;27(1):90–6.PubMedCrossRef

52.

Renko M, Tapanainen P, Tossavainen P, Pokka T, Uhari M. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care. 2011;34(1):230–5.PubMedCrossRef

53.

Meiland R, Geerlings SE, Stolk RP, Netten PM, Schneeberger PM, Hoepelman AI. Asymptomatic bacteriuria in women with diabetes mellitus: effect on renal function after 6 years of follow-up. Arch Intern Med. 2006;166(20):2222–7.PubMedCrossRef

54.

Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet JT, Schneeberger PM, et al. Consequences of asymptomatic bacteriuria in women with diabetes mellitus. Arch Intern Med. 2001;161(11):1421–7.PubMedCrossRef

55.

Harding GK, Zhanel GG, Nicolle LE, Cheang M. Group MDUTIS. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med. 2002;347(20):1576–83.PubMedCrossRef

56.

Ooi ST, Frazee LA, Gardner WG. Management of asymptomatic bacteriuria in patients with diabetes mellitus. Ann Pharmacother. 2004;38(3):490–3.PubMedCrossRef

57.

Cai T, Koves B, Johansen TE. Asymptomatic bacteriuria, to screen or not to screen - and when to treat? Curr Opin Urol. 2017;27(2):107–11.PubMedCrossRef

58.

Trautner BW. Asymptomatic bacteriuria: when the treatment is worse than the disease. Nat Rev Urol. 2011;9(2):85–93.PubMedCrossRef

59.

Schneeberger C, Erwich JJHM, van den Heuvel ER, Mol BWJ, Ott A, Geerlings SE. Asymptomatic bacteriuria and urinary tract infection in pregnant women with and without diabetes: Cohort study. Eur J Obstet Gynecol Reprod Biol. 2018;222:176–81.PubMedCrossRef

60.

Lerman-Garber I, Calva-Mercado JJ, Martínez-Sibaja C, del Castillo CF, Sánchez-Javier RM, Lara E, et al. Leukocyturia in women with diabetes and its clinical implications. Arch Med Res. 2000;31(2):210–5.PubMedCrossRef

61.

Søraas A, Sundsfjord A, Sandven I, Brunborg C, Jenum PA. Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae–a case-control study in a low prevalence country. PLoS One. 2013;8(7):e69581.PubMedPubMedCentralCrossRef

62.

Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med. 2012;366(11):1028–37.PubMedCrossRef

63.

García-Tello A, Gimbernat H, Redondo C, Meilán E, Arana DM, Cacho J, et al. Prediction of infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: development of a clinical decision-making nomogram. Scand J Urol. 2018;52(1):70–5.PubMedCrossRef

64.

Vinken JEM, Mol HE, Verheij TJM, van Delft S, Kolader M, Ekkelenkamp MB, et al. Antimicrobial resistance in women with urinary tract infection in primary care: no relation with type 2 diabetes mellitus. Prim Care Diabetes. 2018;12(1):80–6.PubMedCrossRef

65.

Stapleton A. Urinary tract infections in patients with diabetes. Am J Med. 2002;113(Suppl 1A):80S-S84.PubMedCrossRef

66.

DeYoung GR, Ashmead S. Screening for and treating asymptomiatic bacteriuria not useful in women with diabetes. J Fam Pract. 2003;52(2):98–9.PubMed

67.

ZalmanoviciTrestioreanu A, Lador A, Sauerbrun-Cutler MT, Leibovici L. Antibiotics for asymptomatic bacteriuria. Cochrane Database Syst Rev. 2015;4(4):CD009534.

68.

Grigoryan L, Zoorob R, Wang H, Horsfield M, Gupta K, Trautner BW. Less workup, longer treatment, but no clinical benefit observed in women with diabetes and acute cystitis. Diabetes Res Clin Pract. 2017;129:197–202.PubMedCrossRef

69.

Patterson JE, Andriole VT. Bacterial urinary tract infections in diabetes. Infect Dis Clin North Am. 1995;9(1):25–51.PubMedCrossRef

70.

Wan YL, Lee TY, Bullard MJ, Tsai CC. Acute gas-producing bacterial renal infection: correlation between imaging findings and clinical outcome. Radiology. 1996;198(2):433–8.PubMedCrossRef

71.

Grupper M, Kravtsov A, Potasman I. Emphysematous cystitis: illustrative case report and review of the literature. Medicine (Baltimore). 2007;86(1):47–53.PubMedCrossRef

72.

Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med. 2000;160(6):797–805.PubMedCrossRef

73.

Amano M, Shimizu T. Emphysematous cystitis: a review of the literature. Intern Med. 2014;53(2):79–82.PubMedCrossRef

74.

Arsene C, Saste A, Arul S, Mestrovich J, Kammo R, Elbashir M, et al. A case series of emphysematous pyelonephritis. Case Rep Med. 2014;2014:587926.PubMedPubMedCentralCrossRef

75.

Ubee SS, McGlynn L, Fordham M. Emphysematous pyelonephritis. BJU Int. 2011;107(9):1474–8.PubMedCrossRef

76.

Vollans SR, Sehjal R, Forster JA, Rogawski KM. Emphysematous pyelonephritis in type II diabetes: a case report of an undiagnosed ureteric colic. Cases J. 2008;1(1):192.PubMedPubMedCentralCrossRef

77.

Park BS, Lee SJ, Kim YW, Huh JS, Kim JI, Chang SG. Outcome of nephrectomy and kidney-preserving procedures for the treatment of emphysematous pyelonephritis. Scand J Urol Nephrol. 2006;40(4):332–8.PubMedCrossRef

78.

Chiu PF, Huang CH, Liou HH, Wu CL, Wang SC, Chang CC. Long-term renal outcomes of episodic urinary tract infection in diabetic patients. J Diabetes Complicat. 2013;27(1):41–3.CrossRef

79.

Gandhi J, Dagur G, Warren K, Smith NL, Khan SA. Genitourinary complications of diabetes mellitus: an overview of pathogenesis, evaluation, and management. Curr Diabetes Rev. 2017;13(5):498–518.PubMedCrossRef

Titel: Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: a Review
verfasst von: Reza Pishdad
Paul G. Auwaerter
Rita R. Kalyani
Publikationsdatum: 01.03.2024
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 5/2024
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-024-01537-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: a Review

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin